NCT05787808招募中不适用
The Effect on Bone Marker and Body Mineral Density (BMD) of Daily Jarlsberg Cheese Intake in Risk Patient for Osteoporosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Meddoc
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Bone Mineral Density
研究概览
简要总结
The aim is to compare the daily intake of Calsium (Ca) + vitamin D with and without daily optimal efficacy dose (OED) of Jarlsberg on Bone Mineral Density (BMD) and bone markers (BM) to Osteopeni patients (OP).
- The study population consists of OP-patients of post-menopausal women and men above 55 years of age. OP patients are defined as patients with a T-score below 0.0, but larger than -2.5.
- The study will be performed as a randomized, single-blinded Norwegian multicentre trial with stratified semi-cross-over design with gender and site as stratification factors. The OP-patients included in the study will be allocated to one of the two treatment groups by block randomization with random block size between 2 and 6.
- Women in post-menopausal age have a daily OED Jarlsberg of 45 gram and men in the same age interval have a daily OED of 55 gram.
- The main response variable will be the change in Bone Mineral Density (BMD),total Osteocalcin (tOC) and different bone markers (BM).
- Participants, who fulfil the inclusion criteria, do not meet any of the exclusion criteria and willing to give informed consent to participate will be included and receiving 40µg vitamin D and 500 mg Ca tablets per day, but asked not to eat Jarlsberg cheese the following week. During this week demographic data, bloodsampling for measurement of Osteocalcin and BM and diet registration will be performed.In the clinical study, all the included patients will continue with Ca+ vitamin D, but half of the patient will additionally receive daily OED of Jarlsberg cheese. After 16 weeks, all the patients will receive both Ca+vitamin D and OED of Jarlsberg for addionally 16 weeks. The total duration of the study will be 32 weeks for the patients initially allocated to Jarlsberg and 48 weeks for those allocated only to Ca+vitamin D. The patients will be investigated initially and every 16 weeks.
- A total of 30 patients will be included in each of the two groups.
详细描述
Aim
- To estimate the effect of daily optimal efficacy dose (OED) of Jarlsberg cheese on BMD and bone markers to patients with Osteopeni (OP).
- To compare daily intake of Calsium (Ca) and vitamin D with and without OED of Jarlsberg on BMD and bone markers to OP patients.
- To compare daily intake of Ca and vitamin D with and without OED of Jarlsberg on Time-to-Osteoporotic (TTO) treatment is recommended.
Study population consists of OP-patients of post-menopausal women and men above 55 years of age. OP patients are defined as patients with a T-score below 0.0, but larger than -2.5.
Women in post-menopausal age have a daily OED Jarlsberg of 45 gram and men in the same age interval have a daily OED of 55 gram.
The cheese will be delivered in package of 250 gram with slices of 15.625gram. 45 gram represents 3 slices; 55 gram 4 slices. All the included patients will receive 20µg vitamin D and 1000 mg Ca. Half of the patients will receive vitamin D and Ca-tablets plus Jarlsberg cheese (Treatment group I) and other half only vitamin D and Ca-tablets (Treatment group II).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
盲法说明
Masking is not posible in this study
入排标准
- 年龄范围
- 55 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Osteopeni patients (OP) of both genders above 55 years of age. OPs are defined as patients with T-score below 0.0 but larger than -2.5.
排除标准
- •• Eating disorder
- •Known gastrointestinal disorder.
- •Abnormal liver or kidney function.
- •Diabetes mellitus type I.
- •Diabetes type II without sufficient control.
- •Suffering from verified cancer.
- •Under systemic treatment with corticosteroids or other immunosuppressive drugs the last 3 weeks before start of the trial treatment.
- •Under active antiresorptive treatment or anabolic treatment.
- •Participating in another clinical trial with pharmaceuticals the last six weeks before start of this trial treatment.
- •Known milk product allergy.
- •Not able to understand information.
- •Do not want or not able to give written consent to participate in the study.
结局指标
主要结局
Bone Mineral Density
时间窗: Week 48
g/cm2
次要结局
- Procollagen type 1 N-terminal propeptide (PINP)(Week 48)
- Osteocalcin(week 48)
- Bone specific ALP (BALB)(Week 48)
- Cross-linked C-telopeptide type I collagen (CTX)(week 48)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Effect of Vitamin D and Calcium Supplement on Overall Body Bone Density and Implant Stability in Posterior MaxillaDental ImplantNCT06673485Al-Azhar University12
已完成
3 期
Effect of Calcium and Vitamin D on Bone Loss From the HipOsteoporosisNCT00357643Tufts University450
已完成
不适用
Effectiveness of Calcium and Vitamin D, With and Without Collagen Peptide, in Enhancing Bone Mineral Density on Postmenopausal Women With OsteopeniaOsteopeniaNCT06464718Frontier Medical and Dental College, Abbotabad30
已完成
不适用
Effect of steroid on Bone health in children during treatment of initial episode of Nephrotic Syndrome and role of vitamin D and calcium supplementation in them.CTRI/2017/06/008780VMMC and Safdarjung Hospital New Delhi40
已完成
2 期
The Effect of Vitamin D and Calcium on Bone in Pediatric HIVHIV InfectionBone MassNCT00724178National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)59